Inhibikase Therapeutics Announces Closing of Initial Public Offering

Inhibikase Therapeutics Announces Closing of Initial Public Offering
ATLANTA, Dec. 28, 2020 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase"), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders that arise inside and outside of the brain, announced today the closing of its ... read more
Source: PR NewswirePublished on 2020-12-28